Quantanova deal completes biolitec's PDT (photodynamic therapy) portfolio
This article was originally published in Clinica
Executive Summary
German company biolitec, which develops and produces light-activated drugs for photodynamic therapy (PDT), last week acquired UK-based Quantanova. Jena-based biolitec says the deal will help it gain a leading position in the PDT market earlier than expected.